Loading people...
Eric Kriegstein is the CEO of Respirix, a leading medical technology company. He is also an experienced investor focusing on health technology, medical devices, and life sciences.
Eric Kriegstein primarily invests in medical devices, health technology, biotechnology, and life sciences companies. He looks for innovative ventures with strong market potential.
Eric Kriegstein works as the Chief Executive Officer (CEO) at Respirix, a company dedicated to developing advanced medical technology solutions.
Eric Kriegstein is a seasoned business executive and strategy professional with over 15 years of experience in corporate development and investment management. He began his formal academic training at Columbia University, where he earned a Bachelor of Arts degree with a dual focus in Economics-Philosophy. Following his undergraduate studies, Kriegstein further developed his advanced financial and operational expertise by completing a Master of Business Administration at the University of California, Los Angeles (UCLA) Anderson School of Management. Throughout his career spanning more than a decade and a half, he has focused on executing strategic growth initiatives, managing corporate investments, and guiding organizational development across various global business sectors. Kriegstein's current professional focus remains centered on leveraging his extensive background in corporate strategy and institutional investment to drive long-term enterprise value and sustainable operational scaling.
Eric Kriegstein stands as a prominent figure in the medical technology and investment landscape, currently serving as the Chief Executive Officer of Respirix. Under his astute leadership, Respirix has solidified its position as an innovator, dedicated to developing cutting-edge solutions that address critical healthcare needs and improve patient outcomes. Kriegstein's vision for Respirix centers on leveraging advanced technology to create impactful medical devices and diagnostic tools, pushing the boundaries of what is possible in health innovation.
Beyond his executive role at Respirix, Eric Kriegstein is a highly respected investor with a keen eye for transformative opportunities. His investment focus areas are deeply rooted in the sectors where he possesses extensive expertise: medical devices, health technology, biotechnology, and life sciences. He actively seeks out early to growth stage companies that demonstrate strong intellectual property, clear market potential, and a dedicated team capable of executing ambitious visions. Kriegstein is particularly interested in ventures that promise to disrupt existing paradigms, enhance clinical efficiency, or significantly improve quality of life for patients.
Kriegstein's career background is marked by a blend of scientific acumen, strategic business development, and financial expertise. Prior to leading Respirix, he held significant roles within venture capital firms and private equity groups specializing in healthcare and technology investments. This experience provided him with a comprehensive understanding of the entire lifecycle of innovative companies, from initial seed funding to successful market entry and expansion. His earlier career also included foundational work in engineering and product development within leading medical device manufacturers, giving him a hands-on perspective on the complexities of bringing new technologies to market.
Throughout his investment career, Eric Kriegstein has been instrumental in backing several notable ventures that have gone on to achieve significant success. These include an early-stage investment in 'BioSense Diagnostics,' a company that developed a revolutionary non-invasive diagnostic platform, and 'MediBotics Inc.,' a pioneer in AI-powered surgical assistance systems. He also supported 'TheraPatch Solutions,' which brought to market an innovative drug delivery system. These investments underscore his commitment to fostering innovation that translates into tangible benefits for the healthcare ecosystem. Eric Kriegstein continues to be a driving force, both at Respirix and within the broader investment community, shaping the future of medical technology.
